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Buthionine sulphoximine-mediated sensitisation of etoposide-resistant
human breast cancer MCF7 cells overexpressing the multidrug
resistance-associated protein involves increased drug accumulation
E Schneider', H Yamazaki2*, BK Sinha2 and KH Cowan'
'Medicine Branch and 2Clinical Pharmacology Branch, National Cancer Institute, Bethesda MD 20892, USA.
Summary Preincubation ofetoposide-resistant human MCF7 breast cancer cells (MCF7/VP) with buthionine
sulphoximine (BSO) resulted in their sensitisation to etoposide and vincristine. Chemosensitisation was
accompanied by elevated intracellular drug levels. In contrast, simultaneous exposure to BSO did not result in
increased drug accumulation. Similar, but quantitatively smaller, effects were also observed when sensitive
wild-type MCF7/WT cells were treated with BSO. In agreement with its effect on drug accumulation, BSO
pretreatment also increased VP-16-stimulated cleavable complex formation between DNA topoisomerase II
and cellular DNA. BSO treatment also led to a significant increase in acid-precipitable VP-16 levels in
MCF7/VP, but not MCF7/WT cells. In contrast, no clear effects of BSO on drug efflux were observed and
drug retention was only minimally increased after BSO treatment of both MCF7/WT and MCF7/VP cells and
no difference between the two cell lines was detected. Thus, chemosensitisation by BSO appeared to be
mediated through increased intracellular drug concentrations and/or protein binding.
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Increased intracellular glutathione (GSH) levels as well as
increased activity of GSH-dependent enzymes have been
associated with multidrug resistance in some studies, whereas
others have failed to find evidence for a role of GSH or its
dependent enzymes in multidrug resistance (reviewed in Mos-
cow and Dixon, 1993). However, several studies have shown
that treatment of cells with buthionine sulphoximine (BSO),
an inhibitor of y-glutamylcysteine synthetase, results in the
depletion ofintracellular glutathione and increased sensitivity
of cells to several drugs, including melphalan, anthracycines
and etoposide (Green et al., 1984; Hamilton et al., 1985;
Dusre et al., 1989; Lutzky et al., 1989; Mans et al., 1992).
Studies with doxorubicin-resistant HL60 cells (HL60/AR)
have demonstrated that BSO treatment enhances the sensiti-
vity of the resistant cells to the anthracycline daunorubicin
and that this is accompanied by an increase in intracellular
drug accumulation and retention (Lutzky et al., 1989; Golla-
pudi and Gupta, 1992). Similar results have also been
reported with unselected drug-sensitive human lung, ovarian
and breast carcinoma cells (Mans et al., 1992). In contrast,
BSO treatment does not enhance doxorubicin sensitivity in
multidrug-resistant small-cell lung cancer H69AR cells, de-
spite GSH depletion (Cole et al., 1990). Thus,. although
pharmacological depletion of GSH results in sensitisation of
some cells to cytotoxic drugs, it is unclear whether this is a
direct consequence of GSH depletion or whether the two
effects occur independently.
A doxorubicin-selected, multidrug-resistant MCF7 human
breast carcinoma cell line (MCF7/ADR) with increased GSH
S-transferase levels that exhibits significant cross-resistance to
etoposide has been described (Batist et al., 1986), suggesting
that GSH-mediated mechanisms might contribute to etopo-
side resistance. However, these cells also highly overexpress
MDR1, which can also result in cross-resistance to etoposide.
We have recently described a VP-16-selected, multidrug-
resistant MCF7 subline (MCF7/VP) that does not express
MDR1 mRNA, but instead contains 15-fold elevated levels
of mRNA for the multidrug resistance-associated protein
MRP (Schneider et al., 1994). These cells are 30 to 60-fold
resistant to VP-16, 9-fold resistant to doxorubicin and 5- to
15-fold resistant to vincristine, and resistance is, at least in
part, due to a reduction in intracellular drug concentrations.
In the present study we examined the effects of BSO treat-
ment on the drug sensitivity of MCF7/VP cells. These studies
demonstrated that BSO pretreatment resulted in greater sen-
sitivity of MCF7/VP cells to VP-16 and vincristine and that
chemosensitisation is associated with an increase in intracel-
lular drug accumulation.
Materials and methods
Materials
All materials were as previously described (Schneider et al.,
1994) unless otherwise stated. Buthionine sulphoximine was
obtained from Sigma (St Louis, MO, USA) and a 50mM
stock solution was prepared in water. [3H]VP-16 was obtain-
ed from Moravek (Brea, CA, USA) and [3H]vincristine was
obtained from NEN (Wilmington, DE, USA).
Cell lines
The selection of VP-16-resistant MCF7 (MCF7/VP) human
breast cancer cells and culture conditions of wild-type
(MCF7/WT) and VP-16 resistant MCF7 (MCF7/VP) cells
were previously described (Schneider et al., 1994).
Growth inhibition assays
Cell growth assays were generally performed over a period of
7 days, using the sulphorhodamine B assay (Skehan et al.,
1990) and IC5o values were determined as previously de-
scribed (Schneider et al., 1994). 2.5 JgM BSO was added from
stock solutions as indicated at the same time as the cytotoxic
drug. In some experiments, 50 JM BSO was added 24 h
before addition of VP-16 or vincristine and cells were
incubated for an additional 24 h together with the cytotoxic
drug. Thereafter, the drug-containing medium was removed
and replaced with fresh drug- and BSO-free medium. Drug
effects were then determined after a further 6 days' incuba-
tion. Under either of these conditions, survival of the cells in
the presence of BSO alone was greater than 80%.
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Drug uptake and efflux studies were done essentially as de-
scribed previously (Schneider et al., 1994). To study the effect
of BSO on drug uptake, MCF7/WT and MCF7/VP cells
were incubated for 2 h with 100 JM [3H]VP-16 (1 JACi ml-')
or 31 nM [3H]vincristine (0.25 JCi ml-') in the absence or
presence of BSO in serum-free culture medium, after which
time the cells were analysed for retained radioactivity as
described. To study the effect of glutathione depletion on
drug accumulation and drug efflux, the cells were prein-
cubated with 2.5 JiM or 50 gM BSO for 5 days or 24 h,
respectively, before adding the radioactive drug. After
incubation for 2 h with 1I00 LM [3H]VP-16 (1 ftCi ml-') or
31 nM [3H]vincristine (0.25ftCi ml-') in serum-free medium,
the cells were washed with ice-cold phosphate-buffered saline
(PBS), further incubated with prewarmed serum-and drug-
free medium for 0-60 min, after which time the cells were
again washed in ice-cold PBS and either directly lysed and
assayed for remaining radioactivity or acid precipitated with
10% trichloroacetic acid. The precipitates were solubilised
with 1 M sodium hydroxide and remaining radioactivity
determined by scintillation counting.
Potassium/SDS precipitation assay
MCF7/WT and MCF7/VP cells were incubated with 1 JiCi
ml-' [3H]thymidine for 3 days. Approximately 105 radio-
labelled cells were then placed into each well of a 24-well
culture plate and incubated for 2-3 h to allow them to
adhere. The cells were then further incubated for 1 h in the
absence or presence of 50 JM VP-16, either with or without
2.5 gM BSO or 50 gM BSO to determine the effect of these
modulators on cleavable complex formation. Some cells were
also preincubated for 5 days with 2.5 JM BSO or for 24h
with 50 JM BSO before determining cleavable complex for-
mation in the presence of the same amount of BSO. Cells
were lysed and protein-DNA complexes formed measured as
previously described (Schneider et al., 1988).
Measurements ofglutathione andglutathione transferase levels
Glutathione levels were assayed by the kinetic assay of Tietze
(1969). Glutathione S-transferase activity was assayed by
monitoring the conjugation of glutathione with 1-chloro-2,4-
dinitrobenzene (Habig et al., 1974).
Protein determination
Protein concentrations
Bradford, (1 976).
were determined by the method of
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Results
Effect ofBSO on drug sensitivity andglutathione levels
Intracellular GSH levels have been suggested to affect the
sensitivity of cells to cytotoxic drugs. Therefore, we examined
the effect of BSO on VP-16- and vincristine-mediated growth
inhibition in MCF7/WT and MCF7/VP cells. As shown in
Table I, co-incubation with 2.5psM BSO for 7 days decreased
the IC50 of VP-16 in MCF7/VP cells 2.2-fold, whereas the
sensitivity of MCF7/WT cells remained essentially unchang-
ed. The results were similar when vincnstine was used as the
cytotoxic drug instead of VP-16.
Since BSO is known to reduce the intracellular levels of
GSH, we investigated whether BSO-mediated sensitisation of
MCF7/VP cells was associated with GSH depletion. The data
presented in Table II show that GSH levels in resistant
MCF7/VP cells were approximately 25% lower than in sen-
sitive MCF7/WT cells and that they were further reduced by
50-60% in MCF7/VP cells after continuous treatment with
2.5 m BSO for 5 days. This result suggested that the sen-
sitisation of MCF7/VP cells by BSO may be mediated
through the depletion of GSH. To further study this possi-
bility, cells were preincubated with 50tLM BSO for 24 h
which resulted in an 80-90% reduction in GSH levels in
both cell lines (Table II). When cells were preincubated for
24 h in the presence of 50 SAM BSO, followed by 24h co-
incubation with 50;M BSO and VP-16, MCF7/VP cells
Table II Glutathione, glutathione transferase and the effect of
buthionine sulphoximine in MCF7/WT and MCF7/VP cells
BSO GSH GST
Cell line (4m) (nmolmg-') (nmolmg-'min-')
MCF7/WT 0 113.5 ± 16.4 22.9
(22.3,23.5)
2.Sa 54.4 25.0
(52.1,56.6) (28.8,21.1)
50b 20.6 ND
(28,13.1)
MCF7/VP 0 85.1 ± 4.7 20.0
(17.7,22.3)
2.5a 34.7 25.7
(36.2,33.2) (23.6,27.9)
50b 7.7 ND
(6.8,8.6)
MCF7/WT and MCF7/VP cells were incubated for 5 days with
a2.5 ym BSOa, or for 24 h with 50yiM BSOb before assaying for GSH
levels and GST activity as described in Materials and methods.
Standard errors are given where more than two experiments were
performed; otherwise high and low values are given. ND, not
determined.
Table I Modulation of VP-16 and vincristine cytotoxicity by BSO in MCF7/WT and MCF7/VP cells
MCF7/WT MCF7/VP
Fold
Fold Fold Fold reduction in
Treatment IC50 ±s.e. (nm) sensitisation IC50 ±s.e. (nM) sensitisation resistance resistance
VP-16a 79 ±16 1 4830 ±1190 1 61
VP-16a+2.5gM BSO 62 ±17 1.3 2220 ±590 2.2 36 1.7
VP-16b 210 ±64 1 22375 ± 3060 1 106
VP-16b+50 lM BSO 81 ±20 2.6 4355 ±430 5.1 54 2.0
Vincristinea 0.23 ±0.06 1 3.7 ±0.9 1 16
Vincristinea 0.13 ±0.02 1.8 0.9 ±0.25 4.1 6.6 2.4
+2.5 LM BSO
Vincristineb 0.5 ±0.11 1 24.7 ±5.3 1 49
Vincristineb 0.15 ±0.01 3.4 0.5 ±0.18 49 3.4 14
+5011M BSO
Cells were incubated with VP-16 or vincristine in the presence or absence of BSO as described in Materials and methods.
a2.5gM BSO or water was added at the time of cytotoxic drug addition and cells were incubated in the presence of both
agents for 7 days. bCells were preincubated with or without 50gM BSO alone for 24 h, followed by co-incubation with
VP-16 or vincristine for another 24 h. After removal of BSO and cytotoxic drug, incubation was continued for 6 days in
drug- and BSO-free medium. ICu values were then determined graphically from growth inhibition curves. Values given
are means from at least three experiments±standard errors.Chemosensitsalon in breast cancercells
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became even more sensitised to VP-16 than with continuous
co-treatment (Table I). Interestingly, while the sensitivity of
MCF7/VP cells to VP-16 increased 5-fold, the sensitivity of
MCF7/WT cells also increased 2-fold under these conditions.
Furthermore, despite the sensitisation of MCF7/VP cells by
BSO, the resistant cell line remained significantly less sen-
sitive to VP-16 than parental MCF7/WT cells incubated in
the absence of BSO. In contrast, MCF7/VP cells that were
incubated with BSO became as sensitive to vincristine
(IC50 = 0.5 nM) as parental MCF7/WT cells incubated with-
out BSO (IC50 = 0.5 nM). Thus, when compared with paren-
No BSO
2.5 gM BSO, acute treatment
M 50 gM BSO, acute treatment
E 2.5 gM BSO, 5 days' pretreatment
0 50 gM BSO, 24 h pretreatment
a
c
4)
0
a
E
co
MCF7/WT MCF7NP
b
c
0. a
6
E
CL
C.
> C
MCF7/WT MCF7NP
Figure 1 Effect of BSO on VP-16 (a) and vincristine (b) uptake
into MCF7/WT and MCF7/VP cells. Exponentially growing
MCF7/WT and MCF7/VP cells were incubated for 2h with
1001IM [3H]VP-16 or 31 nm [3H]vincristine at 37C in the presence
or absence of 2.5 LM or 50 ftM BSO, which was added at the same
time as VP-16 or vincristine (acute treatment); to test the effect of
GSH depletion, cells were preincubated for 5 days with 2.5 #AM
BSO or for 24 h with 50 giM BSO, followed by 2 h of co-
incubation with VP-16 or vincristine and BSO. The cells were
then washed and the remaining radioactivity determined by liquid
scintillation counting. The results shown are the means ± s.e. of
at least three experiments. P-values were determined by Student's
t-test.
tal MCF7/WT cells in the absence of BSO, BSO was able to
completely reverse vincristine, but not VP-16, resistance of
MCF7/VP cells. No significant differences in total GST
activities between the two cell lines were observed when
incubated either in the absence or in the presence of 2.5 0tM
BSO for 5 days (Table II).
Effect ofBSO on drug uptake
We had previously shown that VP-16 and vincristine accum-
ulation in drug-resistant MCF7/VP cells is 2- to 3-fold lower
than in sensitive parental MCF7/WT cells, indicating that a
defect in drug accumulation is at least partially responsible
for the observed drug resistance (Schneider et al., 1994). To
examine the possibility that the increased growth-inhibitory
effect of VP-16 and vincristine in the presence of BSO is
mediated through increased intracellular drug concentrations,
the accumulation of VP-16 and vincristine was measured in
both cell lines in the absence or presence of 2.5 gLM or 50gLM
BSO. As shown in Figure la and lb, incubation of MCF7/
WT and MCF7/VP cells with VP-16 or vincristine for 2 h in
the presence of 2.5 LM or 50 gLM BSO (acute treatment) had
little effect on intracellular drug levels, suggesting that BSO
by itself did not directly affect drug accumulation. However,
since growth inhibition was determined under conditions of
reduced GSH levels, it was possible that drug accumulation
was only altered in GSH-depleted cells. Indeed, after deple-
tion of GSH by preincubation of cells for 5 days with 2.5IlM
BSO or for 24 h with 50 JLM BSO, intracellular drug levels
were 40-60% higher in MCF7/VP cells, whereas no
significant increase in drug accumulation was observed in
MCF7/WT cells pretreated with BSO (Table III). Thus, it
appeared that the increased sensitivity of MCF7/VP cells to
cytotoxic drugs following prolonged exposure to BSO was
associated with decreased intracellular GSH and increased
intracellular drug concentration.
Protein-DNA complexformation
Cytotoxicity of VP-16 is mediated through the dose-depen-
dent stimulation of cleavable complex formation between
DNA topoisomerase II and the cellular DNA. We therefore
examined whether the increase in intracellular VP-16 concen-
tration after preincubation with BSO would also result in an
increased formation of drug-induced protein-DNA com-
plexes. As shown in Figure 2, increased cleavable complex
formation was only observed when the cells had been prein-
cubated with BSO, concomitant with the elevated intracel-
lular drug levels. In contrast, there was no direct effect of
BSO on VP-16-stimulated cleavable complex formation. This
result was consistent with the hypothesis that the sensitisa-
tion of MCF7/VP cells by BSO pretreatment was associated
with an increase in intracellular drug concentration and con-
comitant increase in drug-induced topoisomerase II-mediated
DNA strand breaks. Furthermore, in light of the reduced
susceptibility of topoisomerase II in the resistant cells to
cleavable complex formation (Schneider et al., 1994), this
increase in cleavable complex formation is likely to be
significant for the cells' drug sensitivity.
Effect ofBSO on drug efflux, retention andprotein binding
In order to determine whether the elevated drug levels found
in MCF7/VP cells following BSO pretreatment were due to a
reduction in drug efflux or due to increased drug retention,
cells were preincubated with or without 2.5 gM BSO or 50 jAM
BSO alone for 5 days or 24 h, respectively, followed by
incubation for 2 h with radioactive VP-16. After washing in
ice-cold PBS, the cells were incubated for an additional
0-60 min in drug-free medium. At the indicated times total
and acid-precipitable radioactivity remaining was then deter-
mined. As shown in Figure 3, there was no clear difference in
drug efflux between untreated cells and cells that had been
pretreated with BSO, although a small effect of 50 JAM BSO
pretreatment on VP-16 efflux from MCF7/VP cells cannot be
740Chemosensiltsatlon in breast cancercells
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Table III The effect of two different BSO regimens on VP-16 and vincristine
accumulation and sensitivity in MCF7/WT and MCF7/VP cells
Relative GSH Relative drug levels Fold sensitisation
Cell line BSO (JIM) levels (%) VP-16 Vincristine VP-16 Vincristine
MCF7/WT 0 100 100 100 1 1
2.5a 48 100 114 1.3 1.8
50b 18 106 105 2.6 3.4
MCF7/VP 0 100 100 100 1 1
2.5a 41 135 132 2.2 4.1
50b 9 163 148 5.1 49
a2.5tlm BSO was added at the time ofcytotoxic drug addition and cells were incubated in
the presence of both agents for 7 days (growth inhibition assay) or were preincubated for
5 days before measuring GSH levels and drug accumulation. bCells were preincubated
with 501lM BSO alone for 24 h before measuring GSH levels or drug accumulation, or
co-incubated with VP-16 or vincristine for another 24 h followed by 6 days without BSO
and cytotoxic drug (growth inhibition assay).
* No VP-16,no BSO
EZ 50 gMVP-16, no BSO
3 50 ,uM VP-16, 2.5gM BSO,acute treatment
M 50 gM VP-16, 50 gM BSO,acute treatment
M 50 ,uM VP-16, 2.5 giM BSO, 5 days' pretreatment
Em 50 gM VP-16, 50 ,UM BSO,24 h pretreatment
MCF7/WT MCF7/VP
Figure 2 Effect of BSO on VP-16-induced cleavable complex
formation in MCF7/WT and MCF7/VP cells. The formation of
DNA topoisomerase II-DNA cleavable complexes in MCF7/WT
and MCF7/VP cells induced by a I h incubation with 50 JiM
VP-16 in the presence or absence of 2.5 JIM or 50 JiM BSO was
examined by K/SDS precipitation assay. For acute treatment
BSO was added at the same time as VP-16; to test the effect of
GSH depletion, cells were preincubated for 5 days with 2.5 jIM
BSO or for 24 h with 50liM BSO, followed by I h co-incubation
with VP-16 and BSO. The results shown are the means ± s.e. of
three experiments. P-values were determined by Student's t-
test.
excluded. Furthermore, following BSO treatment total retain-
ed radioactivity after 1 h in both cell lines was not
significantly increased. In contrast, a statistically significant
increase (35%, P = 0.04) in acid-precipitable VP-16 was
detected in MCF7/VP cells, whereas the amount of tightly
bound drug remained unchanged in MCF7/WT cells after
BSO treatment (Figure 4).
Discussion
Chemosensitisation of cells by BSO is generally associated
with glutathione depletion and is thought to be related to
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Figure 3 Effect of BSO on VP-16 efflux from MCF7/WT and
MCF7/VP cells. Cells were pretreated with 2.5 1M BSO for 5
days or 501LM BSO for 24h, followed by 2 h incubation with
100ILM [3H]VP-16. After washing in ice-cold PBS, the cells were
further incubated in drug-free medium. At the indicated times,
the cells were lysed and remaining radioactivity determined by
liquid scintillation counting. MCF7/WT: (T) no BSO; (O)
2.5jiM BSO; (0) 50JIM BSO. MCF7/VP: (A) no BSO; (0)
2.5p4M BSO; (V) 50gM BSO.
changes in the metabolism of cytotoxic drugs. However,
some studies have also examined the possible effect of BSO
on drug accumulation and/or intracellular drug distribution.
For example, Lutzky et al. (1989) investigated the effect of
BSO on glutathione and drug levels as well as on intracel-
lular drug distribution in a doxorubicin-resistant HL60 cell
line, HL60/AR, which has been shown to overexpress p190,
the product of the MRP gene (Marquardt et al., 1990; Krish-
namachary and Center, 1993). Following pretreatment with
BSO, drug sensitivity as well as intracellular accumulation
and retention of daunorubicin were increased in the resistant
but not the sensitive parental cells, although GSH levels were
similarly reduced in both cell lines. Mans et al. (1992) have
shown that in MCF7, A2780 and SW-1573 cells BSO treat-
ment reduces GSH concentrations in a time-dependent man-
ner, accompanied by increased intracellular VP-16 levels and
cytotoxicity. These authors also suggested that the effect of
BSO on VP-16 accumulation is not due to a direct inhibition
of drug transport by BSO. Similarly, in the current study we
found that BSO had no direct effect on drug accumulation or
741
z
a
cox
a- E
Q u
,C.2
0 X
co
m
% E
c o
._r
'O
r_Chemosensitisation in breast cancercells
$0 E Schneider etal
7A2
* No BSO treatment, taken as 100% for
2.0 _ both retention and protein binding
D Drug retention with 50gM BSO
m Drug-protein binding with 50 gM BSO
E 0
(D 1.5 - O o
0~~~~
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Figure 4 Effect of BSO on VP-16 retention and protein binding.
Cells were pretreated with or without 50JLM BSO for 24 h, fol-
lowed by 2 h in the presence of 50jiM BSO and 100giM [3H]VP-
16. After a further I h in the absence of VP-16, the cells were
analysed for remaining radioactivity (drug retention) and acid-
precipitable radioactivity (protein binding).
efflux. Rather, pretreatment of the resistant cells with BSO
was required in order for BSO to affect drug accumulation.
Although the BSO-mediated increase in drug accumulation
was accompanied by increased drug-mediated growth inhibi-
tion and GSH depletion in MCF7/VP cells, only minimally
higher drug levels and drug sensitivity were observed in
MCF7/WT cells, despite similar GSH depletion (Table III).
These results suggest that GSH depletion may be necessary
but not sufficient for increased drug sensitivity and accumula-
tion. However, MCF7/VP cells contained lower basal levels
of GSH than the parental MCF7/WT cells, suggesting that,
in addition to decreased drug accumulation, resistance in
MCF7/VP cells may also be associated with lower GSH
levels. Similarly, decreased GSH levels were also noted in
drug-resistant HL60/AR and H69AR cells, both of which
had GSH levels 2- to 6-fold lower than their drug-sensitive
parental cell lines (Lutzky et al., 1989; Cole et al., 1990).
Thus, it remains unclear what, if any, role pharmacological
GSH depletion may have in altering drug sensitivity and
accumulation in MCF7/VP cells.
Studies by Haim. (1987a, b) have shown that metabolites
of VP-16 can covalently bind to proteins and DNA, and it
was suggested that the bound metabolites are reactive and
potentially damaging and capable of causing cellular injury
and cell death. Thus, it is possible that the relative increase in
acid-precipitable VP-16 in MCF7/VP cells after BSO treat-
ment was, at least in part, responsible for the increased
cytotoxicity. The non-effluxable pool of VP-16 in sensitive
MCF7/WT cells was 3-fold higher than that in resistant
MCF7/VP cells (135 ± 10 vs 47 ± 2 pmol of bound VP-16 per
mg of protein for sensitive and resistant cells respectively). A
similar difference was also observed in HL60 and HL60/AR
cells (Politi and Sinha, 1989). Upon incubation with BSO,
there was a 35% increase in the non-effluxable pool in
MCF7/VP cells, whereas the amount of bound drug remain-
ed unchanged in MCF7/WT cells. Consequently, the ratio of
bound VP-16 between sensitive MCF7/WT and resistant
MCF7/VP cells decreased from 3- to 2-fold upon BSO treat-
ment (144 ± 23 vs 63 ± 6 pmol of bound VP-16 per mg of
protein for sensitive and resistant cells respectively). Thus, it
is conceivable that the increased sensitisation of MCF7/VP
cells by BSO resulted from an increase in the pool of non-
effluxable VP-16.
Alternative mechanisms for BSO-mediated increases in
drug sensitivity of cells have been proposed. For example,
Mans et al. (1992) have suggested that BSO may cause
membrane alterations which may affect cellular drug efflux.
However, when Gollapudi and Gupta (1992) measured the
effect of BSO on plasma membrane potential in HL60 and
HL60/AR cells they were unable to detect any alterations,
although the concentration of BSO and the time of exposure
used in these experiments is unclear. Thus, it is not clear
whether BSO can directly affect the plasma membrane. In
contrast, Lutzky et al. (1989) suggested in their study that
BSO might have affected intracellular distribution of GSH/
GST, which in turn may have led to increased drug accum-
ulation and retention. Whether these two effects were related
or independent remained unanswered. We have at present no
evidence that either of these potential mechanisms con-
tributed to the BSO-mediated chemosensitisation of MCF7/
VP cells.
It was recently suggested that the multidrug resistance-
associated protein (MRP), which is overexpressed in the
MCF7/VP cells, functions as an efflux pump for glutathione-
conjugated compounds (GS-X) (Ishikawa, 1992; Jedlitschky
et al., 1994). Thus, one might expect that depletion of GSH
would lead to a reduction in the amount of conjugated
substrate for GS-X and consequently result in higher int-
racellular drug concentrations. However, it is unclear if such
a mechanism is responsible for the observed sensitisation of
MCF7/VP cells by BSO, since neither VP-16 nor vincristine
is a substrate for GSH conjugation (Tew, 1994).
In conclusion, we have shown that BSO is able to sensitise
resistant MCF7/VP cells and that this effect is mediated
through an increase in intracellular drug concentration. Our
results suggest that GSH depletion may be necessary but not
sufficient for increased drug sensitivity and accumulation. In
addition, increased drug binding in the resistant cells may
also contribute to their sensitisation. However, additional
experiments are required to define further the mechanism(s)
involved in BSO-mediated chemosensitisation of MCF7/VP
cells.
Abbreviations: P-gp, P-glycoprotein; MRP, multidrug resistance-
associated protein; WT, wild-type; MDR, multidrug resistance; s.e.,
standard error; PBS, phosphate-buffered saline; IC50, drug concentra-
tion that inhibited cell growth by 50% under the assay conditions
used; BSO, buthionine sulphoximine.
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